OncoMatch

OncoMatch/Clinical Trials/NCT06381960

Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe

Is NCT06381960 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fuzheng Quxie Recipe and Fuzhengquye Fang Recipe simulant for lung cancer.

Phase 2RecruitingJianhui TianNCT06381960Data as of May 2026

Treatment: Fuzheng Quxie Recipe · Fuzhengquye Fang Recipe simulantTo address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative driver gene expression, there is a lack of effective diagnostic and therapeutic measures. Based on this, investigators propose to carry out a clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage lung cancer with negative driver gene expression with the formula of supporting the positive and dispelling the evil.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: ALK wild-type

Required: PD-L1 (CD274) expression <1% (<1%)

Required: EGFR wild-type

Required: PDCD1 expression <1% (<1%)

Required: ROS1 wild-type

Disease stage

Required: Stage IIA, IIB, IIIA

clinical stage IIA-IIIA lung adenocarcinoma after radical surgery

Performance status

OTHER 0–2

Prior therapy

Must have received: radical surgery

after radical surgery (patients within 6 weeks after surgery)

Lab requirements

Blood counts

white blood cell count >3.5 × 10^9/L and <12 × 10^9/L, platelet count >80 × 10^9/L, erythrocyte pressure area >0.20

Kidney function

creatinine <350 μmol/L

Liver function

blood bilirubin <68 μmol/L, aspartate aminotransferase <90 IU/L

Cardiac function

no serious heart disease

Patients with basically normal blood and biochemical indices, etc., without serious viral or bacterial infections; patients without organ failure and serious heart disease (blood bilirubin <68 μmol/L, aspartate aminotransferase <90 IU/L, creatinine <350 μmol/L, white blood cell count >3.5 × 10^9/L and less than 12 × 10^9/L, platelet count >80 × 10^9/L, and (erythrocyte pressure area >0.20)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify